This is a working overview of alpha-MSH, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Bromazepam, sold under many brand names, is a benzodiazepine. It is mainly an anti-anxiety agent with similar side effects to diazepam. In addition to being used to treat anxiety, bromazepam may be used as a premedication prior to minor surgery. Bromazepam typically comes in doses of 1.5 mg, 3 mg and 6 mg tablets. It was patented in 1961 by Roche and approved for medical use in 1974.
Coding regions are composed of codons, which are decoded and translated into proteins by the ribosome; in eukaryotes usually into one and in prokaryotes usually into several. Coding regions begin with the start codon and end with a stop codon. In general, the start codon is an AUG triplet and the stop codon is UAG ("amber"), UAA ("ochre"), or UGA ("opal"). The coding regions tend to be stabilized by internal base pairs; this impedes degradation. In addition to being protein-coding, portions of coding regions may serve as regulatory sequences in the pre-mRNA as exonic splicing enhancers or exonic splicing silencers.
== Equipment == The facility has a custom-made 3 mega-volt tandem accelerator mass spectrometer. It also has a 200 sample ion source, a high resolution, 120° injection magnet, a 90° high energy analysis magnet (mass-energy product 350 MeV-AMU), a 65°, 1.7 m radius electric analyzer and a 2 channel gas ionization detector. The spectrometer weighs around 44 tons and is around 25 metres long. The facility can be seen through a two-storey window in the lobby of the Advanced Research Complex. The spectrometer accelerates the isotopes to a very high speed with almost no contamination, thus allowing for the detection of trace isotopes at very low levels.
Sources: en.wikipedia.org
By 1859, Cuba still did not have a Grand Lodge, and to accelerate this work, they contacted one of the most powerful figures of Freemasonry in the United States at the time, and today the most controversial figure in the history of North American Freemasonry, Albert Pike, requesting his guidance and assistance. Pike was at that time the Grand Commander of the Supreme Council of the Southern Jurisdiction of the United States for the Scottish Rite at Charleston, South Carolina.On March 26, 1859, Albert Pike gave his personal authority to the Cuban exile Andrés Cassard to create new offices, degrees, and bodies of the Scottish Rite in Cuba. However, later that year, Albert Pike and Albert Mackey also granted this authority to others in Cuba. Whether Cassard was aware of that is unclear. Four initiates from Fraternidad Lodge No. 387 joined three Cuban Freemasons living in Hudson, New York to formally petition the Grand Lodge of South Carolina to grant authority for a third Lodge. San Andres Lodge No. 93 was chartered in November 17, 1859. On November 27, 1859, the Grand Lodge of South Carolina granted a warrant to merge the three Cuban Lodges into the first Grand Lodge seen in Cuba in almost four decades; the Gran Logia de Colón (English: Grand Lodge of Columbus) at Santiago de Cuba. Under the authority Grand Lodge of Colon, the three Lodges were restructured as Fraternidad Lodge No.1, Prudencia Lodge No. 2, and San Andres Lodge No. 3. Francisco Griñán y Mozo served as the first Grand Master of the Grand Lodge of Colon.
=== Criteria for a cleansing agent === Wound cleansing forms an integral part of wound management and generally suggests the application of a fluid to aid the removal of surface contaminants, bacteria, and debris from the wound surface and surrounding skin. Water as a cleansing agent, especially in chronic wounds has been proposed and is widely used especially in the management of infected wounds. Despite the plethora of work focussing on the value of water/saline in wound cleansing there is no current consensus as to whether water has an active role to play in the promotion of healing. With this unclear position in mind, alternative cleansing agents such as antiseptics that possess the potential to improve clinical outcomes should be considered. The use of antiseptics on open wounds is justified in terms of prevention/treatment of infection and improved healing outcomes. Criteria by which a wound cleansing agent could be deemed suitable for use on wounds include:
Crabby Joe's is a restaurant and bar chain founded in 1996 with 15 Ontario locations and headquarters in Mississauga. "Obsidian Group Inc." has made the decision to swap some of their Crabby Joe's restaurants to "Chuck's Roadhouse". In 2025, the chain had 15 locations across southern Ontario.
Sources: en.wikipedia.org
A traditional application of methylene blue is the intravital or supravital staining of nerve fibers, an effect first described by Paul Ehrlich in 1887. A dilute solution of the dye is either injected into tissue or applied to small freshly removed pieces. The selective blue coloration develops with exposure to air (oxygen) and can be fixed by immersion of the stained specimen in an aqueous solution of ammonium molybdate. Vital methylene blue was formerly much used for examining the innervation of muscle, skin, and internal organs. The mechanism of selective dye uptake is incompletely understood; vital staining of nerve fibers in skin is prevented by ouabain, a drug that inhibits the Na/K-ATPase of cell membranes.
In 1981, Ceaușescu began an austerity programme designed to enable Romania to liquidate its entire national debt (US$10,000,000,000). To achieve this, many basic goods—including gas, heating and food—were rationed, which reduced the standard of living and increased malnutrition. The infant mortality rate grew to be the highest in Europe. The secret police, the Securitate, had become so omnipresent that it made Romania a police state. Free speech was limited and opinions that did not favor the Romanian Communist Party (PCR) were forbidden. The large numbers of Securitate informers made organised dissent nearly impossible. The regime deliberately played on this sense that everyone was being watched to make it easier to bend the people to the Party's will. Even by Soviet Bloc standards, the Securitate was exceptionally brutal. Ceaușescu created a cult of personality, with weekly shows in stadiums or on streets in different cities dedicated to him, his wife and the Communist Party. There were several megalomaniac projects, such as the construction of the grandiose House of the Republic (today the Palace of the Parliament)—the biggest palace in the world—the adjacent Centrul Civic and a never-completed museum dedicated to Communism and Ceaușescu, today the Casa Radio. These and similar projects drained the country's finances and aggravated the already dire economic situation. Thousands of Bucharest residents were evicted from their homes, which were subsequently demolished to make room for the huge structures.
Hypoglycemia is a condition that occurs when blood glucose levels decrease below normal, causing symptoms including anxiety, tremors, nausea, palpitations, confusion, and coma. Individuals with diabetes or other conditions that result in low blood sugar may carry glucose tablets, oral glucose gel, hard candy, or sugar packets to use when their blood sugar becomes too low. Severe low blood sugar can lead to confusion, coma, neurological damage and other potentially serious complications, making it unsafe to administer glucose by mouth. In these cases, dextrose (D-glucose) can be administered into a vein to quickly and directly raise blood glucose levels.
== External links == Tetrodotoxin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Tetrodotoxin: essential data (1999) Tetrodotoxin from the Bad Bug Book at the U.S. Food and Drug Administration website New York Times, "Whatever Doesn't Kill Some Animals Can Make Them Deadly" U.S. National Library of Medicine: Hazardous Substances Databank – Tetrodotoxin
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.